scholarly journals Pulmonary Artery Pressures Decrease Over Time during Heart Failure Management Guided by Ambulatory Hemodynamic Monitoring in Real World Setting

2016 ◽  
Vol 22 (8) ◽  
pp. S8
Author(s):  
William T. Abraham ◽  
Rita Jermyn ◽  
David Shavelle ◽  
Arvind Bimaraj ◽  
Kunjat Bhatt ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Artery ◽  
Hemodynamic Monitoring ◽  
Real World ◽  
Heart Failure Management ◽  
Real World Setting ◽  
Over Time

scholarly journals REAL WORLD ANALYSIS OF OUTCOMES OF REMOTE PULMONARY ARTERY HEMODYNAMIC MONITORING IN HEART FAILURE PATIENTS OF DIFFERENT AGE GROUPS

2021 ◽  
Vol 77 (18) ◽  
pp. 681
Author(s):  
Mansi Oberoi ◽  
Muhammad Hamza Saad Shaukat ◽  
Smitha Narayana Gowda ◽  
Adam Stys ◽  
Tomasz Stys ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Artery ◽  
Hemodynamic Monitoring ◽  
Real World ◽  
Age Groups ◽  
Heart Failure Patients

Baseline characteristics and clinical features of patients with heart failure with reduced ejection fraction: a European real-world, non-interventional registry study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
U Zeymer ◽  
L.H Lund ◽  
V Barrios ◽  
C Fonseca ◽  
A.L Clark ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Real World ◽  
Nyha Class ◽  
Funding Source ◽  
Class Iii ◽  
Reduced Ejection Fraction ◽  
Cardioverter Defibrillator ◽  
Real World Setting ◽  
The Mean

Abstract Background Heart failure (HF) is a major medical and economic burden that is often managed in office based practices. Recently, the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) was introduced as novel therapeutic option into European guidelines for the management of HF. The ARIADNE registry aims to provide information on how outpatients with HF with reduced ejection fraction (HFrEF) are managed in Europe, in light of this novel treatment option. Methods ARIADNE was a prospective registry of patients with HFrEF treated by office-based cardiologists (OBC) or selected primary care physicians (recognized as HF specialists; PCP) in a real world setting. HFrEF patients were included prospectively, independently of whether treatment had been changed recently or not. 9069 patients were recruited from 687 centres in 17 European countries. Results The mean age of all patients was 68.1 years (S/V: 67.3 years, Non-S/V: 68.9 years). The majority of patients were in NYHA class II (61.3%), or NYHA class III (37.1%) overall, while more patients in the S/V group showed NYHA class III (S/V: 42.8%, Non-S/V: 30.9%). Mean LVEF was slightly lower in the S/V group than in the Non-S/V group (S/V: 32.7%, Non-S/V: 35.4%, overall 34.0%). The most frequently observed signs of HF were dyspnoea upon effort, followed by fatigue, palpitations on exertion at baseline. More patients tend to have more severe symptoms in the S/V groups (e.g. for dyspnoea on effort, Non-S/V: moderate 40.8%, severe 8.6%; S/V: moderate 46.4%, severe 14.1%). 44.0% of patients from the S/V group and 39.3% of non-S/V patients reported at least one hospitalization within 12 months prior to baseline, of which 73.3% in S/V and 69.9% in non-S/V patients were due to HF., At baseline, 44.7% of the patients used a CV device, of which most were implantable cardioverter defibrillator (ICD: Non-S/V 54.2%, S/V: 52.8%), implantable cardioverter defibrillator (CRT-ICD:Non-S/V 21.9%, S/V: 27.0%), and pacemaker (Non-S/V: 13.4%, S/V: 10.5%). The mean KCCQ overall summary score was 62.6 in the S/V group and 69.5 in the Non-S/V group at baseline. 83.9% of patients were treated with ARB or ACEi in Non-S/V group, (ACEi 57.3%, ARB 26.9%). The most frequently taken drug combinations in either group were ACEi/ ARB or S/V with β -blockers (Non-S/V 69.3%, S/V 67.3%). 40.2% in the Non-S/V group and 42.9% in S/V groups used a combination of ACEi/ARB or S/V, β-blocker and MRA. Conclusions The ARIADNE prospective registry provides insights and reflects variations in HF treatment practices in outpatients in Europe and the way S/V was introduced by OBCs and specialized PCPs in a real-world setting. In the observed population, S/V is more often prescribed to slightly younger patients with slightly lower LVEF, there was a greater observed percentage of S/V patients NYHA class III, with lower quality of life measurements and with more severe symptoms and recent hospitalizations for heart failure. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Novartis Pharma AG

Abstract 3143: Reverse Hemodynamic Remodelling May Be Possible Over Time

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Lynne W Stevenson ◽  
Yong K Cho ◽  
J. T Heywood ◽  
Robert C Bourge ◽  
William T Abraham ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Pulmonary Artery ◽  
Right Ventricular ◽  
Nyha Class ◽  
Systolic Pressure ◽  
Filling Pressure ◽  
Class Iii ◽  
One Year ◽  
Over Time

Introduction : Elevated filling pressures are a hallmark of chronic heart failure. They can be reduced acutely during HF hospitalization but the hemodynamic impact of ongoing therapy to maintain optivolemia has not been established. Methods and Results : After recent HF hospitalization, 274 NYHA Class III or IV HF patients were enrolled in the COMPASS-HF study at 28 experienced HF centers and received intense HF management (average 24.7 staff contacts/ 6 months) ± access to filling pressure information to adjust diuretics to maintain optivolemia, usually defined as estimated pulmonary artery diastolic (PAD) pressure of 12±4 mmHg. Filling pressure information was available for half the patients during the first 6 months (the Chronicle group, <Access), and for all patients during the next 6 months. Diuretics were adjusted 12.7 times per patient in the Chronicle group and 8.2 times per patient in the Control (-Access) group during the first 6 months (p = 0.0001). Compared to baseline, decreases in RV systolic pressure (RVSP) and ePAD were significant for the +Access patients by one year (p=0.0012 and p =.04, respectively). The Control patients exhibited a similar trend 6 months after crossing to +Access (figure ). Conclusions: Targeted therapeutic adjustments, based on continuous filling pressures along with intensification of HF management contacts, are associated with a reduction in chronic left-sided filling pressures and right ventricular load.

scholarly journals Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure†

2009 ◽  
Vol 11 (1) ◽  
pp. 77-84 ◽  
Author(s):  
Francesco Orso ◽  
Samuele Baldasseroni ◽  
Gianna Fabbri ◽  
Lucio Gonzini ◽  
Donata Lucci ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Real World ◽  
Beta Blockers ◽  
Italian Survey ◽  
Real World Setting

scholarly journals Pulmonary Artery Pressure-Guided Heart Failure Management is Associated with Slower Decline in Kidney Function

2019 ◽  
Vol 25 (8) ◽  
pp. S99
Author(s):  
Nour Tashtish ◽  
Sadeer Al-Kindi ◽  
Steven C. Mitchell ◽  
Guilherme H. Oliveira ◽  
Arash Rashidi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Artery ◽  
Kidney Function ◽  
Pulmonary Artery Pressure ◽  
Heart Failure Management ◽  
Artery Pressure
Sign in / Sign up

Export Citation Format

Share Document